Stockscreener 앱 받기
0.66%
시간 외 거래:
Altimmune Inc 주식(ALT)의 최신 뉴스
Altimmune Stock Price Forecast. Should You Buy ALT? - StockInvest.us
ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff - Stocktwits
ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Evercore Maintains Altimmune(ALT.US) With Buy Rating, Cuts Target Price to $17 - Moomoo
Altimmune’s Phase 3 MASH Trial Puts Pemvidutide in the Spotlight for Investors - TipRanks
ALT Maintained by Evercore ISI Group -- Price Target Lowered to $17 - GuruFocus
Altimmune to Participate in Stifel Cardiometabolic Forum - The Manila Times
Altimmune, Inc. (ALT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Altimmune Inc. (ALT) Edges Higher to $3.27 as Shares Hold Mid-RangeETF Outflow Streak - siam.in
Altimmune, Inc. (ALT) Stock Analysis: Biotech's Potential 431.55% Upside Draws Investor Attention - DirectorsTalk Interviews
Altimmune (ALT) exec gains stock as 24,000 RSUs vest - Stock Titan
Altimmune’s Investigational Therapy For Alcohol Use Disorder Meets Primary Endpoint – ALT Stock Jumps 10% - Stocktwits
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report? - Yahoo Finance
Altimmune at Wells Fargo healthcare conference: pemvidutide push By Investing.com - Investing.com Canada
Altimmune’s (ALT) Three Liver Trials Move Forward At Once - Yahoo Finance
Altimmune Inc. (ALT) Peer Comparison – Compare with Others - Value Research
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference - marketscreener.com
Altimmune (ALT) Trading: Closes 5.42% Higher at $3.11 in the Current Update; Price Setup: the Supplied Trading Band Runs From $2.95 to $3.27 in Latest TradingValue Area Low - careplusvn.com
Altimmune (NASDAQ:ALT) Trading Up 9.2%Should You Buy? - MarketBeat
ALT Stock Drops Pre-Market On Dilution Fears – Retail Calls It A ‘Horror Story’ - Stocktwits
Altimmune Inc (ALT) News, Articles, Events & Latest Updates - Stocktwits
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger? - Yahoo Finance
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus - Yahoo Finance
HC Wainwright Estimates Altimmune's Q3 Earnings (NASDAQ:ALT) - MarketBeat
LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff? - Stocktwits
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Altimmune (ALT) Rises 2.08% to $2.94 as Shares Hold Above Key SupportActive ETF Flow - Vinanet
Altimmune Inc (ALT) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
9 Health Care Stocks Whale Activity In Today’s Session - Benzinga
Altimmune (ALT) Q2 2026 Earnings Call: PERFORMA Starts, Cash Reaches $519M - TradingKey
ALT|Altimmune Inc|Price:3.110|Chg%:+0.160 - TradingKey
Altimmune (ALT) President and CEO Jerome Durso Buys 15,000 Shares - GuruFocus
Altimmune CEO Jerome Benedict Durso Buys 15,000 Shares at $2.95 Each - Kalkine Media
Altimmune (ALT) CEO Jerome Durso purchases 15,000 shares at $2.95 each - Stock Titan
Altimmune: Pemvidutide Performs, But A Long Wait Ahead (NASDAQ:ALT) - Seeking Alpha
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus - The Globe and Mail
Barclays Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Altimmune Inc RECLAIM Phase 2 Trial in AUD Topline Results Conference Call Transcript - GuruFocus
Q3 2025 Altimmune Inc Earnings Call Transcript - GuruFocus
Altimmune (NASDAQ:ALT): What Does the Latest Update Mean for Trial Execution? - kalkinemedia.com
Altimmune Inc Phase 2b Topline 48-Week Data Conference Call Transcript - GuruFocus
Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT - MarketBeat
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ... - Yahoo Finance Australia
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancin - GuruFocus
Altimmune Reports Q2 2026 Financial Results and SEC Filing Highlighting Increased Assets and Equity Raise - kalkinemedia.com
Altimmune, Inc. Q2 2026: Revenue $0 EPS $(0.12) — 10-Q Summary - TradingView
Altimmune (ALT) grows cash reserves above $518M while advancing Phase 3 MASH trial - Stock Titan
Altimmune (ALT) Advances Clinical Trials Amidst High Price-to-Sa - GuruFocus
Altimmune Releases Q2 2026 Financial Results - AlphaStreet
William Blair Maintains Altimmune(ALT.US) With Hold Rating - Moomoo
Altimmune (NASDAQ:ALT) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
3.06%
2.55%
자본화:
|
볼륨(24시간):